ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 346

Sclerostin Protects Against Inflammatory Bone Loss by Regulating Tnfalpha Mediated p38-Mapkinase Activation

Corinna Wehmeyer1, Christina Wunrau1, Athanasios Stratis1, Ina Kramer2, Michaela Kneissel2, Thomas Pap3 and Berno Dankbar1, 1Institute of Experimental Musculoskeletal Medicine (IEMM), University Hospital Muenster, Muenster, Germany, 2Novartis Institutes for Biomedical Research, CH-4056 Basel, Switzerland, 3Institute of Experimental Musculoskeletal Medicine, University Hospital Muenster, Muenster, Germany

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: animal models and tumor necrosis factor (TNF), rheumatoid arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis: Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Progressive loss of joint structure is a hallmark of rheumatoid arthritis (RA). TNFα has been shown to promote the destruction of bone by increasing the number of bone-resorbing osteoclasts and decreasing the number of bone-forming osteoblasts. The Wnt-Inhibitor sclerostin negatively regulates osteoblast differentiation and the disruption of this endogenous inhibitor increases the ability of Wnts to stabilize β-catenin and stimulate osteogenesis. Since it has been shown that sclerostin is upregulated in response to TNFα, we studied its role in inflammatory arthritis using the hTNF transgenic (hTNFtg) mice model of RA.

Methods: Sclerostin expression was assessed by immunohistochemistry, Western-blot-analysis, and RT‑PCR. The localisation of β-catenin was determined by immunfluorescence staining. Western-blot-analysis was used to evaluate p38-MAPK phosphorylation. Sclerostin knockout (SOST-/-) mice were crossed with hTNFtg mice to generate TNFα overexpressing mice that lack sclerostin (SOST-/-hTNFtg). Clinical disease severity, bone erosion, cartilage destruction and synovial inflammation in SOST-/-hTNFtg and hTNFtg mice were evaluated by histomorphometric, x-ray and micro-CT analysis. hTNFtg mice were treated with blocking antibodies against murine sclerostin or control-vehicle.

Results: Immunhistological staining revealed high expression of sclerostin in synovial tissue of hTNFtg ankle joints, especially in infiltrating synovial-like fibroblasts (SF). Only negligible staining was observed in wildtype animals. In vitro, hTNFtg SF expressed sclerostin whereas wildtype did not. Unexpectedly, radiographic, microCT and histopatological examination of hind paw joints of SOST-/-hTNFtg mice demonstrated that the loss of sclerostin dramatically accelerated joint damage in this mouse model of RA. SOST-/-hTNFtg mice displayed significantly more synovial hyperplasia, proteoglycan loss and bone erosion compared to hTNFtg mice. Moreover, injection of a neutralizing antibody to murine sclerostin in hTNFtg mice did not improve clinical signs of arthritis and but led to elevated inflammation as well as bone erosion. In vitro, upon stimulation of hTNFtg and SOST-/-hTNFtg SF with recombinant Wnt3a, β-catenin translocated to the nucleus, but this was not affected by loss of sclerostin. Of note, recombinant sclerostin was able to inhibit the TNFα induced p38-MAPK activation of wildtype SF.

Conclusion: Since p38-MAPK signalling specifically regulates inflammation induced bone loss, our data strongly suggest a protective function of sclerostin against TNFα-mediated joint destruction by inhibition of TNFα induced p38-activation in synovial fibroblasts. The blockade of inflammatory cytokine action proposes a complete novel function of sclerostin.


Disclosure:

C. Wehmeyer,
None;

C. Wunrau,
None;

A. Stratis,
None;

I. Kramer,
None;

M. Kneissel,
None;

T. Pap,
None;

B. Dankbar,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sclerostin-protects-against-inflammatory-bone-loss-by-regulating-tnfalpha-mediated-p38-mapkinase-activation/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology